The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab

Bookmark and Share
Published: 23 Jun 2020
Views: 834
Rating:
Save
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Dr Josep Ribera speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He discusses the NEUF study which looks at the treatment of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia with blinatumomab in a real-world setting.

He outlines the trial design, results and toxicity profile.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

The NEUF study is a project led by Amgen and the main objective of this project is to know the results of the use of blinatumomab as part of compassionate use therapy in real clinical practice. This NEUF study has two big parts: one on the use of blinatumomab in Philadelphia chromosome negative patients and the other is in the Philadelphia chromosome positive ALL patients. This is the abstract that will be presented by Sabina Chiaretti in the EHA meeting.

In a cohort of adult patients with Philadelphia positive ALL in the situation of relapsed/refractory the use of blinatumomab was associated with a high level of complete response, about 50%, and this has translated to a pretty good rate of molecular response, that is an important objective in any ALL, and of course in Philadelphia positive ALL, of about 75-80%.

The side effects were the same as expected and as seen in the clinical trial, the ALCANTARA clinical trial, that included similar patients with Ph ALL. At the end the number of patients with complete hematologic response, complete molecular response, the feasibility of allogeneic stem cell transplantation and the overall survival were absolutely superimposable to the data obtained in the phase II clinical trial ALCANTARA.

So the main message of the NEUF study for Ph ALL is that in real clinical practice the results of blinatumomab for relapsed refractory Ph ALL are superimposable to those obtained in the phase II clinical trial. This is a very good message for our daily clinical practice.